- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY® and Regeneron's Veloci-Bi® platforms -
- CytomX to receive$37 milliontarget selection payment for two additional programs selected -
- Regeneron secures option to select up to 6 additional future targets bringing total potential target nomination, research, development, regulatory and sales-based milestones covered under the collaboration to up to approximately~$4 billion-
SOUTH SAN FRANCISCO, Calif.,June 03, 2026(GLOBE NEWSWIRE) --CytomX Therapeutics, Inc.(NASDAQ: CTMX) today announced an expansion of its collaboration and licensing agreement with Regeneron Pharmaceuticals, Inc. to create conditionally-activated bispecific cancer therapies utilizing CytomX’s Probody® therapeutic platform and Regeneron’s Veloci-Bi® bispecific antibody development platform.
The Regeneron and CytomX collaboration, initially entered into in 2022, is strategically focused on applying CytomX’s biologic masking strategies in combination with Regeneron’s bispecific antibodies to develop investigational bispecifics that remain inactive until activated by proteases in the tumor microenvironment. This technology has the potential to widen the therapeutic window and help minimize off-target effects for next-generation T-cell engaging therapies, potentially addressing tumor types that have historically been challenging for immunotherapy.
“Cancer necessitates innovative treatment approaches, and with this expanded collaboration with CytomX, we are advancing bispecific treatments where we see the most promise. Our complementary oncology expertise with CytomX – including application of our proprietary VelociSuite® technologies developed to accelerate drug discovery and development – make us uniquely suited to work together on this endeavor to bring new medicines to patients in need,” saidJohn Lin, M.D., Ph.D., Senior Vice President ofOncology & Antibody Technology Researchat Regeneron.
“Our ongoing research collaboration with Regeneron is based on a shared commitment to cutting edge science and a vision to push the boundaries of cancer immunotherapy. At CytomX, we are applying our deep understanding of masking and protease biology to unlock new opportunities uniquely enabled by our technology,” saidSean McCarthy,D. Phil, CEO and Chairman of CytomX. “Regeneron’s deep expertise in bispecific immunotherapies has made them an ideal partner in expanding the reach of the PROBODY platform, and we look forward to building on our alliance momentum to collectively make a meaningful difference for people with cancer.”
Under the expanded agreement, Regeneron and CytomX will continue to collaborate on discovery activities to identify and validate conditionally active bispecific antibodies. Regeneron will be responsible for funding preclinical and clinical development and commercialization activities. CytomX will receive a target nomination payment of$37 millionfor two additional targets that have been selected, and Regeneron has the option to select up to 6 additional future targets. Total potential target nomination payments, preclinical, clinical, regulatory and commercial milestones covered under the scope of the expanded collaboration could reach up to approximately$4 billion. CytomX is also eligible to receive tiered global net sales royalties on products covered under the collaboration.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).